Built on MVE’s legacy SC 4/2V and 4/3V vapor shipper platform, the next-generation SC 4/2V and 4/3V models have been ...

Celltrion USA announced that Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo), biosimilars referencing Prolia ...

Centauri Therapeutics Limited, an immunotherapy company, has appointed Dr. Debra Barker as Chief Medical Officer (CMO).

Dr. Richard Philipson has been appointed Chief Medical Officer (CMO) of Hansa Biopharma AB, effective July 14.

Cellular Origins has successfully shown that its platform is able to fully automate cell therapy manufacturing processes using validated, off-the-shelf third-party instruments in combination with ...

LOTTE BIOLOGICS will produce antibody drug substance for Ottimo Pharma’s Jankistomig at its Syracuse Bio Campus in New York. James Park, CEO of LOTTE BIOLOGICS, stated, “This agreement serves as ...

The partnership will combine Thermo Fisher’s cell culture and processing technology and Cellular Origins’ CGT robotic manufacturing platform, Constellation, to deliver full, robotic, 24/7 production ...

Philochem AG, a wholly-owned subsidiary of the Philogen Group, and RayzeBio Inc., a wholly-owned subsidiary of Bristol-Myers Squibb, have inked a definitive agreement under which Philochem will ...